These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38845625)

  • 1. International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea.
    Shin EY; Hong YJ; Lim KM; Kim TH; Lee JH
    J Pharm Policy Pract; 2024; 17(1):2354299. PubMed ID: 38845625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of orphan drug designation to cancer treatments (2008-2017): a comprehensive and comparative analysis of the USA and EU.
    Vokinger KN; Kesselheim AS
    BMJ Open; 2019 Oct; 9(10):e028634. PubMed ID: 31601584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
    Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
    Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.
    Cho I; Han E
    Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
    Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
    Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Current Status and Issues in Drug Development for Rare Cancers].
    Kashitani Y; Takayama H; Hamada N; Go S; Tagami M; Sugihara T
    Gan To Kagaku Ryoho; 2023 Nov; 50(11):1150-1154. PubMed ID: 38056864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing surveillance framework of cell and gene therapy products in the European Union, the United States, Japan, South Korea and China: a comparative study.
    Cai Y; Sui L; Wang J; Qian W; Peng Y; Gong L; Wu W; Gao Y
    BMC Med; 2024 Sep; 22(1):421. PubMed ID: 39334246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
    Choi H; Lee H; Park B; Kim C; Lee J
    Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A
    Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delay in Vaccine Access in ASEAN Countries.
    Subsittipong N; Choi J; Kim TH; Han E
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007-2019).
    Lee SH; Yoo SL; Bang JS; Lee JH
    Int J Environ Res Public Health; 2020 Apr; 17(9):. PubMed ID: 32357397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union.
    Balkhi B; Almuaither A; Alqahtani S
    Saudi Pharm J; 2023 Sep; 31(9):101738. PubMed ID: 37638213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea.
    Jeong H; Purja S; Kim E
    Gene Ther; 2024 May; 31(5-6):242-254. PubMed ID: 38200263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matched analysis on orphan drug designations and approvals: cross regional analysis in the United States, the European Union, and Japan.
    Murakami M; Narukawa M
    Drug Discov Today; 2016 Apr; 21(4):544-9. PubMed ID: 26945941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Availability and Affordability of Drugs With a Conditional Approval by the European Medicines Agency; Comparison of Korea With Other Countries and the Implications.
    Kwon HY; Kim H; Godman B
    Front Pharmacol; 2018; 9():938. PubMed ID: 30233363
    [No Abstract]   [Full Text] [Related]  

  • 17. Analysis of Pediatric Drug Approval Lag in Japan.
    Ueyama E; Kaneko M; Narukawa M
    Ther Innov Regul Sci; 2021 Mar; 55(2):336-345. PubMed ID: 32959206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K; Tsutani K
    J Clin Pharm Ther; 2010 Jun; 35(3):289-301. PubMed ID: 20848767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the copayment reduction system on accessibility to orphan drugs in South Korea.
    Hwang SE; Kim M; Hong Y; Lee D; Kim T; Park J; Bae J; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):519-525. PubMed ID: 36922505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Availability of and access to orphan drugs: an international comparison of pharmaceutical treatments for pulmonary arterial hypertension, Fabry disease, hereditary angioedema and chronic myeloid leukaemia.
    Blankart CR; Stargardt T; Schreyögg J
    Pharmacoeconomics; 2011 Jan; 29(1):63-82. PubMed ID: 21073206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.